CRSP Stock Earnings: CRISPR Therapeutics Beats EPS, Misses Revenue for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips
CRSP stock results show that CRISPR Therapeutics beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.
The post CRSP Stock Earnings: CRISPR Therapeutics Beats EPS, Misses Revenue for Q2 2024 appeared first on InvestorPlace.
More From InvestorPlace